• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Cardinal Health Explores Oncologists’ Views on Therapies


Pharmaceutical Executive

Cardinal Health Specialty Solutions, healthcare services and products company, released its second edition of Oncology Insights. The research-based report outlines the views of over 200 oncologists in the US pertaining to the latest medical advances and potential for treatments.

The report found that:

  • Fifty-one percent of oncologists see CAR T-cell therapy as a game-changing approach to cancer treatment, but barriers such as cost, toxicity and complex administration could lead to slow uptake.

  • As more biosimilars enter the U.S. market, oncologists are open to prescribing them in place of their reference products; and 66% have high expectations about the cost savings biosimilars will deliver for their practices.

  • With three targeted therapies recently approved for acute myeloid leukemia (AML), most oncologists (85%) are routinely prescribing genetic tests for AML patients – and a growing number (31%) are now referring AML patients to academic medical centers for treatment.
Related Videos
Ashley Gaines
Related Content